Physician profile
William Cheung
NPI 1629031208
$42,627.06
in general payments reported to CMS, 2019-2025
77 companies · $5,078 in 2025
The $5,078 reported for 2025 was more than what 82% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,771 · 2020: $5,389 · 2021: $7,052 · 2022: $5,883 · 2023: $5,913 · 2024: $5,542 · 2025: $5,078.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Education: $705 · Long Term Medical Supply Or Device Loan: $549.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,279.49 |
| Education | $704.83 |
| Long Term Medical Supply Or Device Loan | $549.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $5,187.76 | 2019-2025 | |
| Gilead Sciences, INC. | $3,698.11 | 2019-2025 | Epclusa, Trodelvy |
| Amgen INC. | $2,837.02 | 2019-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $2,390.02 | 2019-2025 | Breztri, Tagrisso, Farxiga |
| Pfizer INC. | $2,360.04 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $2,193.74 | 2019-2025 | Keytruda, Welireg, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $1,698.98 | 2019-2023 | Reblozyl, Opdualag, Opdivo |
| Janssen Biotech, INC. | $1,519.51 | 2019-2025 | Rybrevant, Darzalex, Erleada |
| Incyte Corporation | $1,486.69 | 2020-2025 | Monjuvi, Jakafi, Pemazyre |
| Glaxosmithkline, LLC. | $1,256.40 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $1,241.01 | 2019-2025 | Linzess, Creon |
| Lilly USA, LLC | $1,122.61 | 2019-2025 | Jaypirca, Verzenio, Mounjaro |
| Novo Nordisk INC | $1,116.54 | 2019-2025 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,081.24 | 2019-2025 | Gilotrif, Jardiance |
| Genzyme Corporation | $963.60 | 2019-2025 |
Show all 77 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $931.75 | 2019-2025 | |
| Exelixis INC. | $731.74 | 2020-2025 | Cabometyx |
| Rigel Pharmaceuticals, INC. | $725.53 | 2019-2025 | Rezlidhia, Tavalisse, Gavreto |
| Seagen INC. | $649.90 | 2020-2025 | Padcev, Tukysa, Adcetris |
| Bayer Healthcare Pharmaceuticals INC. | $610.91 | 2019-2025 | |
| Astellas Pharma US INC | $571.42 | 2019-2025 | Xtandi, Xospata |
| Puma Biotechnology, INC. | $565.27 | 2019-2025 | Nerlynx |
| Genentech USA, INC. | $537.93 | 2019-2022 | |
| Celgene Corporation | $501.86 | 2019-2025 | Reblozyl, Pomalyst, Opdivo |
| Sobi, INC | $487.20 | 2022-2025 | |
| Array Biopharma INC | $406.55 | 2020-2025 | Mektovi, Braftovi, Tukysa |
| Takeda Pharmaceuticals U.S.A., INC. | $378.25 | 2019-2025 | Ninlaro, Iclusig |
| Regeneron Healthcare Solutions, INC. | $349.92 | 2019-2025 | Libtayo |
| Radius Health, INC. | $338.21 | 2019-2022 | |
| Dova Pharmaceuticals | $320.69 | 2019-2021 | |
| Amarin Pharma, INC. | $315.76 | 2019-2023 | |
| Exact Sciences Corporation | $247.20 | 2024-2025 | Cologuard Collection Kit |
| Recordati_rare_diseases_inc. | $227.34 | 2024-2025 | Sylvant |
| Foundation Medicine, INC. | $211.62 | 2020-2023 | |
| Mirati Therapeutics, INC. | $205.70 | 2023-2024 | Krazati |
| Agios Pharmaceuticals, INC. | $205.10 | 2024-2025 | Pyrukynd |
| Pharmacyclics LLC, An Abbvie Company | $184.25 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $166.57 | 2020-2025 | |
| Mannkind Corporation | $165.68 | 2019-2024 | |
| Daiichi Sankyo INC. | $155.86 | 2024-2025 | Enhertu, Datroway |
| Medtronic, INC. | $155.25 | 2022 | |
| Emd Serono, INC. | $143.93 | 2022-2023 | Tepmetko |
| Sanofi-Aventis U.S. LLC | $141.96 | 2019-2020 | |
| Allergan, INC. | $141.91 | 2019-2020 | |
| Esperion Therapeutics, INC. | $128.14 | 2020-2022 | |
| Aveo Pharmaceuticals, INC. | $114.51 | 2022-2025 | |
| Taiho Oncology, INC. | $102.67 | 2023-2025 | |
| Kite Pharma, INC. | $100.53 | 2021-2023 | |
| Teva Pharmaceuticals USA, INC. | $95.91 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $89.22 | 2019-2020 | |
| Vifor Pharma, INC. | $86.51 | 2021-2023 | Veltassa |
| Pharmaessentia USA Corporation | $82.00 | 2024-2025 | Besremi |
| Global Blood Therapeutics, INC. | $80.28 | 2020-2022 | |
| Tesaro, INC. | $68.53 | 2019 | |
| Verastem, INC. | $66.28 | 2019 | |
| Myovant Sciences INC. | $63.94 | 2021 | |
| Clovis Oncology, INC. | $62.90 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $59.67 | 2023 | Orgovyx |
| Seqirus USA INC | $53.67 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $42.57 | 2021-2022 | |
| Eusa Pharma (US) LLC | $41.33 | 2021 | |
| Ibsa Pharma INC. | $34.84 | 2021 | |
| Ironwood Pharmaceuticals, INC | $34.34 | 2019-2022 | |
| Hologic Sales and Service, LLC | $29.77 | 2024 | Localizer, Biozorb, Celero-12 |
| Insmed, INC. | $24.67 | 2025 | Brinsupri |
| Deciphera Pharmaceuticals INC. | $23.95 | 2022 | |
| Genmab U.S., INC. | $23.51 | 2024 | Epkinly |
| Ardelyx, INC. | $21.75 | 2025 | Ibsrela |
| Tempus Ai, INC | $20.87 | 2025 | Xt Cdx |
| Sanofi Pasteur INC. | $20.40 | 2021 | |
| Myriad Genetic Laboratories, INC. | $20.00 | 2021 | |
| Adaptive Biotechnologies Corporation | $19.47 | 2024 | Clonoseq |
| Optinose US, INC. | $19.09 | 2019 | |
| Cti Biopharma Corp. | $18.89 | 2023 | Vonjo |
| Redhill Biopharma INC. | $17.73 | 2020 | |
| Morphosys, US INC. | $16.09 | 2023 | Monjuvi |
| Hikma Pharmaceuticals USA | $14.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Cheung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.